We are pleased to provide you with information on products and services that might be of interest to you.
A SERVICE
ANNOUNCEMENT FROM: |
|
|
|
|
|
Click here to view in your Browser.
 |
 |
You are invited to a morning symposium
If only I'd known about
pre-clinical drug development hosted by QB3 and co-sponsored by Patheon and Deloitte Consulting LLP.
You will have the opportunity to interact with experienced biotech executives, leading academics and industry experts. |
|
| Date: |
Thursday, June 28, 2012
|
| Time: |
8:00 am -2:00 pm |
| Location: |
Byers Auditorium, Genentech Hall
UCSF Mission Bay
600 16th St., San Francisco, CA |
| RSVP: |
Register Here |
|
|
| About This Symposium |
Successfully completing a proof of concept (POC) is a key milestone on the path to commercial success for innovative life science companies. The seeds of a successful POC are planted in pre-clinical development where early decisions can have far reaching consequences for commercial viability.
The California Institute for Quantitative Biosciences (QB3) is hosting a symposium covering the topics of CMC, ADME, and Toxicology, and their impact on the pre-clinical development pathway. Designed for executives of emerging biopharmaceutical companies, the symposium will feature presentations from industry leaders and experts from the University of California, San Francisco (UCSF), and will also include an opportunity for interactive sessions with entrepreneurs at successful life sciences start-ups who will share lessons they have learned.
This event is co-sponsored by Patheon, a leading global provider of contract development and commercial manufacturing services to the pharmaceutical and biotechnology industries and Deloitte Consulting LLP.
Continental breakfast will be served. You are also invited to stay for a buffet lunch and have an opportunity to network with symposia presenters as well as your peers. Please RSVP no later than June 18th!
|
|
| Agenda |
| Time |
Schedule |
8:00-8:30 am |
Registration and Continental Breakfast |
8:30-8:35 am |
Welcome |
8:35-10:35 am |
Why getting to Proof-of-Concept (POC) is so important for commercial success. Trends and Analysis from the Deloitte-RECAP database - Matthew Hudes—Deloitte Consulting
What are Chemistry, Manufacturing and Control (CMC) processes and how does CMC impact your ability to successfully complete a POC? - Mark Kontny—Patheon
What must you do for pre-clinical toxicology and what should you do? - to be announced
Understanding the What, When, Where and How of pre-clinical ADME - to be announced |
10:05-10:30 am |
Break |
10:30-11:30 am |
Unforeseen Hurdles and Lessons Learned the Hard Way - to be announced
Regulatory Trends in the EU and US - to be announced |
11:30 am-12:30 pm |
Selecting the Right Drug Development Partner: What I wish I had known - Moderated roundtable discussion |
12:30-12:45 pm |
Close |
12:45-2:00 pm |
Lunch Buffet and Networking |
|
|
|
|
University of California, San Francisco | QB3 MC: 2522
1700 4th Street, Byers Hall, Suite 214,
San Francisco | CA 94158-2330 | P: (415) 514-9790 | www.qb3.org
|
 |
At QB3 we value your privacy, and should you not wish to receive further messages from us, please click here and your name will be removed from our address book.
QB3 does not, and will not sell or share any personal information, including email addresses, with anyone.
|
|
|
|
|
Pharmaceutical Technology is published by Advanstar Communications, 485 Rt 1 South, Iselin, NJ 08830.
This is an advertisement sent on behalf of this advertiser.
|
|
|